GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Debt-to-EBITDA

China Isotope & Radiation (HKSE:01763) Debt-to-EBITDA : 1.43 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

China Isotope & Radiation's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$238 Mil. China Isotope & Radiation's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,617 Mil. China Isotope & Radiation's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$1,297 Mil. China Isotope & Radiation's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.43.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for China Isotope & Radiation's Debt-to-EBITDA or its related term are showing as below:

HKSE:01763' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.11   Med: 0.81   Max: 1.77
Current: 1.77

During the past 9 years, the highest Debt-to-EBITDA Ratio of China Isotope & Radiation was 1.77. The lowest was 0.11. And the median was 0.81.

HKSE:01763's Debt-to-EBITDA is ranked worse than
58.33% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs HKSE:01763: 1.77

China Isotope & Radiation Debt-to-EBITDA Historical Data

The historical data trend for China Isotope & Radiation's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Debt-to-EBITDA Chart

China Isotope & Radiation Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only 0.99 0.93 0.85 0.77 1.39

China Isotope & Radiation Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 1.27 0.72 1.39 1.43

Competitive Comparison of China Isotope & Radiation's Debt-to-EBITDA

For the Medical Devices subindustry, China Isotope & Radiation's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Isotope & Radiation's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where China Isotope & Radiation's Debt-to-EBITDA falls into.



China Isotope & Radiation Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

China Isotope & Radiation's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(237.557 + 1616.969) / 1337.615
=1.39

China Isotope & Radiation's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(237.557 + 1616.969) / 1296.556
=1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


China Isotope & Radiation  (HKSE:01763) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


China Isotope & Radiation Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


China Isotope & Radiation (HKSE:01763) Business Description

Traded in Other Exchanges
N/A
Address
No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines